Clinical observation of esmolol for acute anterior ST-segment elevation myocardial infarction in patients undergoing PCI
- VernacularTitle:艾司洛尔用于急性前壁ST段抬高型心肌梗死PCI后患者的临床观察
- Author:
Shuhan YANG
1
;
Shu ZHOU
1
;
Yanfeng REN
1
;
Jingjing GUO
1
;
Zengxia WANG
1
;
Zhifang WANG
2
Author Information
1. Cardiac Intensive Care Unit，Xinxiang Central Hospital/Xinxiang Key Laboratory for Critical Care Medicine and Pharmacology/Xinxiang Engineering Technology Research Center of Extracorporeal Life Support，Henan Xinxiang 453000，China
2. Dept. of Cardiology，Xinxiang Central Hospital，Henan Xinxiang 453000，China
- Publication Type:Journal Article
- Keywords:
esmolol;
acute anterior ST-segment elevation myocardial infarction;
percutaneous coronary intervention;
safety
- From:
China Pharmacy
2024;35(23):2903-2907
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the effects of esmolol on cardiac function， inflammatory factors and serum microRNA （miR）-29a and miR-129-5p in patients with acute anterior ST-segment elevation myocardial infarction after percutaneous coronary intervention （PCI）. METHODS A total of 120 patients with acute anterior ST-segment elevation myocardial infarction undergoing PCI in our hospital from April 2021 to June 2023 were selected and divided into control group （60 cases） and study group （60 cases） according to the random number table method. The control group was given conventional treatment， and the study group was additionally given Esmolol hydrochloride injection based on the control group for one week. The levels of cardiac function indexes （left ventricular ejection fraction， left ventricular end-systolic volume index， left ventricular end-diastolic diameter， peak ejection fraction， cardiac output）， inflammatory factors （C-reactive protein， myeloperoxidase， interleukin-6， brain natriuretic peptide， homocysteine） myocardial enzyme indexes （creatine kinase isoenzyme， β2-microglobulin， cardiac troponin Ⅰ）， and serum expression of miR-29a and miR-129-5p were observed in two groups， and the occurrence of ADR was recorded. RESULTS After one week of treatment， left ventricular ejection fraction， peak ejection fraction， cardiac output， and the expression of miR-129-5p in two groups was significantly higher than before treatment （P＜0.05）， while left ventricular end-systolic volume index， left ventricular end-diastolic diameter， inflammatory factors and myocardial enzyme index levels， and the expression of miR-29a were significantly lower than before treatment （P＜ 0.05）. The study group was significantly better than the control group （except for the creatine kinase-MB） （P＜0.05）. There was no statistically significant difference in the incidence of symptomatic hypotension， symptomatic bradycardia， cardiogenic shock， and arrhythmia between two groups （P＞0.05）. CONCLUSIONS Esmolol can improve cardiac function， reduce inflammatory factors， lessen myocardial injury， and regulate serum expressions of miR-29a and miR-129-5p in patients with acute anterior ST- segment elevation myocardial infarction after PCI， with good safety.
